REHOVOT, Israel, May 5, 2020 /PRNewswire/ -- CollPlant
(NASDAQ:CLGN) , a regenerative and aesthetics medicine company,
today announced that it will be hosting a webinar on Tuesday, May 12, 2020 at 11 am EDT/6 pm IDT
that will feature its Co-Founder and Chief Scientist, Professor
Oded Shoseyov and Chief Executive Officer, Mr. Yehiel Tal. The webinar will showcase the
Company's journey to develop transformative patient solutions in
regenerative and aesthetic medicine via its innovative plant-based,
human recombinant collagen (rhCollagen) platform.
- Webinar Topic: Plant-based Collagen for the Future and
Aesthetic & Regenerative Medicine
- Date: Tuesday, May 12,
2020
- Time: 11 am Eastern Daylight
Time /6 pm Israel Daylight
Time
- Registration Link: click here
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. Our products are based on our rhCollagen (recombinant
human collagen) that is produced with CollPlant's proprietary plant
based genetic engineering technology.
Our products address indications for the diverse fields of organ
and tissue repair, and are ushering in a new era in regenerative
medicine. Our flagship rhCollagen BioInk product line is ideal for
3D bioprinting of tissues and organs. CollPlant has a licensing
agreement with United Therapeutics, whereby United Therapeutics is
using CollPlant's BioInks in the manufacture of 3D bioprinted lungs
for transplant in humans. The Company has a collaboration agreement
with 3D Systems to advance and accelerate tissue and scaffold
bioprinting by delivering an integrated 3D printer and BioInks
solution to third parties. CollPlant's industry collaboration
partnerships include the Advanced Regenerative Manufacturing
Institute (ARMI) and RegenMed Development Organization (ReMDO).
For more information about CollPlant,
visit http://www.collplant.com.
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
For example, forward-looking statements include statement regarding
the potential closing of the offering, the expected closing date
and the intended use of proceeds. These statements are often
characterized by terminology such as "believes," "hopes," "may,"
"anticipates," "should," "intends," "plans," "will," "expects,"
"estimates," "projects," "positioned," "strategy" and similar
expressions and are based on assumptions and assessments made in
light of management's experience and perception of historical
trends, current conditions, expected future developments and other
factors believed to be appropriate. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements. Many factors
could cause CollPlant's actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: the Company's history of significant losses, its ability
to continue as a going concern, and its need to raise additional
capital and its inability to obtain additional capital on
acceptable terms, or at all; the impact of the coronavirus
outbreak; the Company's expectations regarding the timing and cost
of commencing clinical trials with respect to tissues and organs
which are based on its rhCollagen based BioInk, dermal fillers for
aesthetics, VergenixSTR, and VergenixFG; the Company's ability to
obtain favorable pre-clinical and clinical trial results;
regulatory action with respect to rhCollagen based BioInk, dermal
fillers for aesthetics, VergenixSTR, and VergenixFG including but
not limited to acceptance of an application for marketing
authorization, review and approval of such application, and, if
approved, the scope of the approved indication and labeling;
commercial success and market acceptance of the Company's
rhCollagen based BioInk, dermal fillers for aesthetics,
VergenixSTR, and VergenixFG; the Company's ability to establish
sales and marketing capabilities or enter into agreements with
third parties and its reliance on third party distributors and
resellers; the Company's ability to establish and maintain
strategic partnerships and other corporate collaborations; the
Company's reliance on third parties to conduct some or all aspects
of its product manufacturing; the scope of protection the Company
is able to establish and maintain for intellectual property rights
and the Company's ability to operate its business without
infringing the intellectual property rights of others; the overall
global economic environment; the impact of competition and new
technologies; general market, political, and economic conditions in
the countries in which the Company operates; projected capital
expenditures and liquidity; changes in the Company's strategy; and
litigation and regulatory proceedings. More detailed information
about the risks and uncertainties affecting CollPlant is contained
under the heading "Risk Factors" included in CollPlant's most
recent annual report on Form 20-F filed with the SEC, and in other
filings that CollPlant has made and may make with the SEC in the
future. The forward-looking statements contained in this press
release are made as of the date of this press release and reflect
CollPlant's current views with respect to future events, and
CollPlant does not undertake and specifically disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events
or otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
Sophia Ononye-Onyia, PhD MPH
MBA
Founder & CEO
The Sophia Consulting Firm
Tel: +1-347-533-4578
E-mail: sophia@sophiaconsultingfirm.com
View original
content:http://www.prnewswire.com/news-releases/collplant-to-host-webinar-highlighting-its-plant-based-human-recombinant-collagen-rhcollagen-platform-for-the-future-of-aesthetic-and-regenerative-medicine-301052694.html
SOURCE CollPlant